Key result
Race-free 2021 CKD-EPI equation impacts the evaluation of GFR-based treatment effects in clinical trials.
Why the study?
Treatment effects on GFR decline are increasingly adopted as end points in RCTs evaluating treatments for chronic kidney disease progression, but the impact of using the race-free 2021 CKD-EPI creatinine equation on these treatment effects is unclear.
Answers are grounded in this paper and cite their sources.
Supports GFR-based endpoints in CKD trials; confirms robust surrogacy for KFRT.
Glomerular filtration rate (GFR)-based end points, either as time-to-event end points or as mean rate of decline in GFR (slope), are possible end points in randomized controlled trials (RCTs) evaluating treatments for the progression of chronic kidney disease. We have previously demonstrated robust trial-level associations between treatment effects on GFR decline and treatment effects on the clinical end point of kidney failure with replacement therapy (KFRT).1,2 Treatment effects on GFR decline are increasingly adopted for use in RCTs.
No takes yet. Share an insight, caveat, or question.
Chaudhari et al. (2023) studied Chronic kidney disease. Race-Free 2021 CKD-EPI Creatinine Equation was evaluated on GFR-based end points. The impact of using the race-free 2021 CKD-EPI creatinine equation on treatment effects on GFR-based endpoints in clinical trials was discussed, with no quantitative results reported in the abstract.
Synapse has enriched 10 related papers. Consider them for comparative context: